- IPH4502 is Innate’s novel and differentiated topoisomerase I
inhibitor antibody drug conjugate (ADC) targeting Nectin-4
Regulatory News:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA)
(“Innate” or the “Company”) today announced that the
U.S Food and Drug Administration (FDA) has cleared its
investigational new drug (IND) application to initiate a Phase 1
clinical study of IPH4502, its novel and differentiated
topoisomerase I inhibitor antibody drug conjugate (ADC) targeting
Nectin-4 in solid tumors. Innate expects to initiate the Phase 1
study in the coming months.
The Phase 1, open-label, multi-center study, includes a Part 1
Dose Escalation and a Part 2 Dose Optimization, and will assess the
safety, tolerability, and preliminary efficacy of IPH4502 as a
single agent in advanced solid tumors known to express Nectin-4,
including but not limited to urothelial carcinoma, non-small cell
lung, breast, ovarian, gastric and colorectal cancers.
“We are thrilled to advance the IPH4502 program, and the IND
application acceptance is an important milestone for Innate, as
this is our first ADC program to enter the clinic,” said Dr
Sonia Quaratino, Chief Medical Officer of Innate Pharma.
“IPH4502 is a novel and differentiated Nectin-4 ADC that has the
potential to provide a new therapeutic option for patients with a
cancer expressing a wide range of Nectin-4. Through this Phase 1
study we aim to advance the research on our ADC technology for the
benefit of patients.”
About IPH4502
IPH4502 is a novel topoisomerase I inhibitor Antibody Drug
Conjugate (ADC) conjugated to exatecan targeting Nectin-4.
Nectin-4 is a cell membrane adhesion protein overexpressed in
several solid tumors, including urothelial, breast, esophageal,
lung, ovarian, and pancreatic cancers, with limited expression in
normal tissues.
In non-clinical models, IPH45 was well tolerated and shows
anti-tumor efficacy in vitro and in vivo.
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology
company developing immunotherapies for cancer patients. Its
innovative approach aims to harness the innate immune system
through therapeutic antibodies and its ANKET®
(Antibody-based NK cell Engager
Therapeutics) proprietary platform.
Innate’s portfolio includes lead proprietary program lacutamab,
developed in advanced form of cutaneous T cell lymphomas and
peripheral T cell lymphomas, monalizumab developed with AstraZeneca
in non-small cell lung cancer, as well as ANKET® multi-specific NK
cell engagers to address multiple tumor types.
Innate Pharma is a trusted partner to biopharmaceutical
companies such as Sanofi and AstraZeneca, as well as leading
research institutions, to accelerate innovation, research and
development for the benefit of patients.
Headquartered in Marseille, France with a US office in
Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq
in the US.
Learn more about Innate Pharma at www.innate-pharma.com and
follow us on Twitter and LinkedIn.
Information about Innate Pharma shares
ISIN code
FR0010331421
Ticker code
Euronext: IPH Nasdaq: IPHA
LEI
9695002Y8420ZB8HJE29
Disclaimer on forward-looking information and risk
factors
This press release contains certain forward-looking statements,
including those within the meaning of applicable securities laws,
including the Private Securities Litigation Reform Act of 1995. The
use of certain words, including “anticipate,” “believe,” “can,”
“could,” “estimate,” “expect,” “may,” “might,” “potential,”
“expect” “should,” “will,” or the negative of these and similar
expressions, is intended to identify forward-looking statements.
Although the Company believes its expectations are based on
reasonable assumptions, these forward-looking statements are
subject to numerous risks and uncertainties, which could cause
actual results to differ materially from those anticipated. These
risks and uncertainties include, among other things, the
uncertainties inherent in research and development, including
related to safety, progression of and results from its ongoing and
planned clinical trials and preclinical studies, review and
approvals by regulatory authorities of its product candidates, the
Company’s reliance on third parties to manufacture its product
candidates, the Company’s commercialization efforts and the
Company’s continued ability to raise capital to fund its
development. For an additional discussion of risks and
uncertainties, which could cause the Company's actual results,
financial condition, performance or achievements to differ from
those contained in the forward-looking statements, please refer to
the Risk Factors (“Facteurs de Risque") section of the Universal
Registration Document filed with the French Financial Markets
Authority (“AMF”), which is available on the AMF website
http://www.amf-france.org or on Innate Pharma’s website, and public
filings and reports filed with the U.S. Securities and Exchange
Commission (“SEC”), including the Company’s Annual Report on Form
20-F for the year ended December 31, 2023, and subsequent filings
and reports filed with the AMF or SEC, or otherwise made public by
the Company. References to the Company’s website and the AMF
website are included for information only and the content contained
therein, or that can be accessed through them, are not incorporated
by reference into, and do not constitute a part of, this press
release.
In light of the significant uncertainties in these
forward-looking statements, you should not regard these statements
as a representation or warranty by the Company or any other person
that the Company will achieve its objectives and plans in any
specified time frame or at all. The Company undertakes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by law.
This press release and the information contained herein do not
constitute an offer to sell or a solicitation of an offer to buy or
subscribe to shares in Innate Pharma in any country.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240922158244/en/
For additional information, please contact:
Investors
Innate Pharma Henry Wheeler Tel.: +33 (0)4 84 90
32 88 Henry.wheeler@innate-pharma.fr
Media Relations
NewCap Arthur Rouillé Tel.: +33 (0)1 44 71 00 15
innate@newcap.eu
Innate Pharma (NASDAQ:IPHA)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Innate Pharma (NASDAQ:IPHA)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024
